Thrivent Financial for Lutherans Buys 11,481 Shares of ResMed Inc. $RMD
Thrivent Financial for Lutherans significantly increased its stake in ResMed Inc. (NYSE:RMD) during the fourth quarter of 2025, purchasing an additional 11,481 shares and bringing its total holdings to 22,408 shares valued at $5.43 million. Other institutional investors also adjusted their positions in ResMed, which recently reported strong quarterly earnings, beating analyst expectations, and announced a quarterly dividend of $0.60 per share. Despite some insider selling, analysts maintain a "Moderate Buy" consensus rating for ResMed.
ResMed Inc stock (US75102W1036): sleep apnea specialist draws attention after latest options moves
ResMed Inc. (RMD) is gaining investor attention due to unusual options activity suggesting higher volatility and its stock trading near recent highs on the NYSE. The company specializes in medical devices and digital health solutions for sleep apnea and chronic respiratory conditions, leveraging a business model that combines hardware and cloud-based software. For US investors, ResMed offers exposure to structural healthcare growth trends, though it requires careful consideration of reimbursement policies and market dynamics.
Robotic surgery gets telepresence, force-sensing tools in Intuitive upgrade
Intuitive (Nasdaq: ISRG) announced significant innovations for its da Vinci 5 robotic surgical system, including enhanced telepresence capabilities, expanded uses for Force Feedback instruments, and improved product reliability and security. These updates aim to advance patient care, optimize surgeon experience, and reduce costs, with features like a full-OR telepresence camera, mobile console login, new training modules, and an anticipated increase in instrument uses by 2027. The company also highlighted strong da Vinci 5 adoption, with over 1,400 systems installed globally and 380,000 procedures performed, along with a guaranteed 98% uptime exceeding 99% actual performance.
ResMed stock (US7611521078): sleep apnea specialist in focus after latest earnings
ResMed, a specialist in sleep apnea and respiratory care, remains a key player after reporting its latest quarterly figures. The company's business model relies on a combination of medical device sales, high-margin consumables like masks, and recurring software revenue from its digital health platforms. Continued growth in mask and accessory sales, cloud-connected devices, and software-as-a-service solutions are highlighted as primary growth drivers.
Is the Options Market Predicting a Spike in ResMed Stock?
This article examines the options market activity for ResMed Inc. (RMD), noting that the Jan. 15, 2026 $150 Call has a high implied volatility, suggesting expectations of a significant price movement. Despite this, ResMed currently holds a Zacks Rank #3 (Hold) with analysts slightly lowering earnings estimates, indicating a potential disconnect between options market sentiment and fundamental outlook. The piece suggests that high implied volatility could present an opportunity for options traders to sell premium.
ResMed Inc. stock rises Wednesday, still underperforms market
ResMed Inc. (RMD) shares rose by 1.00% on Wednesday, closing at $209.86. Despite this gain, the stock underperformed the broader market, as the S&P 500 Index and the Dow Jones Industrial Average both saw larger increases. This marks the third consecutive day of gains for ResMed's stock.
ResMed stock (US7611521078): sleep apnea specialist in focus after latest quarterly results
ResMed (US7611521078) remains a key player in the sleep and respiratory care market, combining medical devices, recurring consumables, and cloud-based software. The company's latest quarterly results highlight strong demand for sleep apnea therapy, emphasizing the role of connectivity and data in patient adherence and navigating payer requirements. Despite operating in a competitive environment, ResMed offers US investors focused exposure to structural healthcare trends driven by sleep disorders and home-based care.
Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference
Resmed (NYSE: RMD, ASX: RMD) announced that its Chairman and Chief Executive Officer, Mick Farrell, and Chief Financial Officer, Aaron Bloomer, will participate in the 46th Annual William Blair Growth Stock Conference on June 2, 2026. Their webcast presentation will begin at approximately 4:40 p.m. Central Time, with a replay available for ninety days afterward. Resmed focuses on life-changing health technologies, pioneering innovative AI-powered digital health solutions and cloud-connected devices for home healthcare.
5,006 Shares in ResMed Inc. $RMD Acquired by North Dakota State Investment Board
The North Dakota State Investment Board recently acquired 5,006 shares of ResMed Inc. (NYSE:RMD), valued at approximately $1.2 million, during the fourth quarter. This acquisition comes as ResMed reported strong quarterly results, exceeding analyst expectations for both EPS and revenue, and announced a quarterly dividend of $0.60 per share. Several other institutional investors have also adjusted their holdings in ResMed, while analysts maintain a "Moderate Buy" consensus rating for the stock despite recent insider selling.
ResMed Rises After Partnership With Oura to Expand Sleep Health Education, Care Pathways
ResMed is partnering with Oura to enhance sleep health education and care pathways. This collaboration aims to integrate Oura's physiological data with ResMed's expertise in sleep and respiratory care, potentially benefiting individuals with sleep conditions. The announcement led to a rise in ResMed's stock.
ResMed stock (US7611521078): sleep apnea specialist in focus after latest quarterly results
ResMed recently reported its latest quarterly results, highlighting strong demand for its sleep apnea devices and masks despite concerns about obesity drugs and supply chain issues. The company's business model combines device sales, recurring revenue from masks, and subscription-like income from digital health software. ResMed remains a key player in the sleep apnea market, with its core drivers being diagnosis volume, device installation, and mask replacements, although long-term impacts from weight-loss drugs and regulatory changes require monitoring.
Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference
ResMed (NYSE: RMD, ASX: RMD) announced that its CEO, Mick Farrell, will participate in a fireside chat at the 46th Annual William Blair Growth Stock Conference on June 4, 2026. The event is scheduled for 1:00 p.m. Central Daylight Time and will be webcast live. A replay will be available on the company’s website following the event.
Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference
Resmed (NYSE: RMD, ASX: RMD) announced that its Chairman and Chief Executive Officer, Mick Farrell, and Chief Financial Officer, Aaron Bloomer, will participate in the 46th Annual William Blair Growth Stock Conference on June 2, 2026. The company will host a webcast presentation for investors, accessible via its investor relations website. Resmed specializes in life-changing health technologies, including digital health solutions and cloud-connected devices, aiming to improve sleep and breathing with care delivered at home.
Silver Economy Investing: Why the Healthcare Giants Are in Focus
The article discusses the "Silver Economy," highlighting how the rapidly aging global population is creating significant growth opportunities in the healthcare sector. It emphasizes how major healthcare companies like Eli Lilly, Tandem Diabetes Care, Intuitive Surgical, and ResMed are capitalizing on this demographic shift through innovation in areas such as obesity, diabetes, robotic surgery, and sleep health. The piece also details specific initiatives by these companies and outlines the financial resilience of the healthcare sector as an investment.
ResMed Inc. stock rises Tuesday, outperforms market
ResMed Inc. (RMD) stock increased by 1.78% to $207.78 on Tuesday, outperforming the broader market which saw the S&P 500 Index and Dow Jones Industrial Average fall. This marked the stock's second consecutive day of gains.
IDEXX Laboratories (Nasdaq:IDXX) - Stock Analysis
This report provides a comprehensive stock analysis of IDEXX Laboratories (IDXX), covering its market performance, financial health, future growth predictions, and recent news. Key highlights include its Q1 2026 revenue growth and increased full-year guidance, driven by strong diagnostics and new product integration like the SDMA kidney biomarker. The analysis also touches on analyst sentiment, insider transactions, and comparisons to competitors.
Oura Ring now links sleep changes to Resmed sleep resources
Oura and Resmed have partnered to provide Oura Ring members in the U.S. with expanded access to sleep health education and care pathways. Oura Ring Gen3 and Ring 4 users can now access Resmed's educational tools, sleep assessments, and connect with independent healthcare providers to address sleep concerns, especially in light of the high rate of undiagnosed obstructive sleep apnea. This collaboration aims to help individuals better understand their sleep patterns and take informed action on potential issues.
Resmed, Oura partner on sleep health education, care
Resmed and Oura have announced a partnership to expand access to sleep health education and care, aiming to help individuals better understand and improve their sleep. The collaboration will allow Oura Ring users with signs of nighttime breathing disturbances to access Resmed's resources, including educational materials, sleep assessments, and connections to healthcare providers. This initiative seeks to bridge the awareness gap regarding sleep disorders like obstructive sleep apnea (OSA) and encourage users to seek clinical evaluation.
Henry Schein stock (US42548G1040): dental distributor in focus after latest quarterly update
Henry Schein, a major dental and medical distributor, recently released new quarterly figures and an updated outlook, drawing investor attention. The article examines the company's business model, key revenue drivers in its dental and medical segments, and the impact of factors like inflation and procedure volumes on its performance. It concludes that while Henry Schein maintains a strong position through recurring sales and technology offerings, it faces ongoing challenges from economic cycles and competitive pricing.
ResMed Inc stock (US75102W1036): sleep apnea specialist in focus after fresh institutional buying
ResMed Inc has attracted new institutional capital, with Passumpsic Savings Bank disclosing a new position, highlighting continued investor interest in the sleep apnea and respiratory care market. The company, trading in the upper part of its 52-week range with a market capitalization of $29.7 billion, specializes in medical technology for sleep-disordered breathing and chronic respiratory conditions. ResMed's business model combines sales of devices like CPAP machines with recurring revenue from consumables and cloud-based software, positioning it as a significant player in the digital health and medical device sectors.
ResMed Inc. stock (US7611521078): Earnings beat and dividend lift focus
ResMed Inc. reported stronger-than-expected quarterly results, including adjusted EPS of $2.86 and revenue of $1.43 billion, marking a 10.8% year-over-year increase. The company also announced a quarterly dividend of $0.60 per share, drawing fresh analyst attention and highlighting its sustained operating momentum in the medical device sector. This positive update reinforces ResMed's position as a key player in sleep apnea therapy and digital health platforms for U.S. investors.
ResMed Inc. stock rises Monday, outperforms market
ResMed Inc. (RMD) stock increased by 1.12% to $204.15 on Monday, outperforming the broader market. This rise occurred during a mixed trading session where the Dow Jones Industrial Average gained, but the S&P 500 Index fell. Despite the day's gain, ResMed Inc. remains significantly below its 52-week high.
Integrated Investment Consultants LLC Invests $1.34 Million in ResMed Inc. $RMD
Integrated Investment Consultants LLC has acquired a new stake worth approximately $1.34 million in ResMed Inc. during the fourth quarter, purchasing 5,545 shares. This investment follows ResMed's strong quarterly results, which surpassed analyst expectations for both EPS and revenue, and the company's recent announcement of a $0.60 quarterly dividend. The article also notes recent institutional activity, analyst ratings, and insider trading in ResMed stock.
Passumpsic Savings Bank Purchases New Stake in ResMed Inc. $RMD
Passumpsic Savings Bank initiated a new position in ResMed Inc. by purchasing 8,952 shares valued at approximately $2.16 million during the fourth quarter. ResMed reported strong quarterly results, with EPS of $2.86 and revenue of $1.43 billion, and declared a quarterly dividend of $0.60 per share. Analysts currently rate ResMed as a "Moderate Buy" with a consensus price target of $286.18.
ResMed Inc. stock (US7611521078): dividend in focus after solid Q3 results
ResMed Inc. has reported solid Q3 2026 results with increased revenue and profitability, alongside declaring a quarterly cash dividend of $0.60 per share, payable on June 18, 2026. Despite operational progress and a strong balance sheet, the stock currently trades below its 52-week high, suggesting potential recovery. The company's core business in sleep and respiratory care, driven by recurring mask sales and digital health solutions, positions it well in a growing market amidst regulatory complexities and competitive pressures.
Inspire Medical Systems (INSP) Is Down 9.5% After Cutting 2026 Outlook And Filing ESOP Shelf Registration - What's Changed
Inspire Medical Systems (INSP) recently reported a Q1 net loss and cut its 2026 revenue outlook to US$825M–US$875M, leading to a 9.5% stock drop. The company also filed an ESOP-related shelf registration and is phasing out its classified board structure. These changes, coupled with reimbursement and WISER program disruptions, signal near-term operational challenges and a shift in its investment narrative, emphasizing execution risk and potential long-run governance improvements.
Stephens Investment Management Group LLC Decreases Position in ResMed Inc. $RMD
Stephens Investment Management Group LLC decreased its stake in ResMed Inc. ($RMD) by 4.1% in the fourth quarter of 2025, selling 11,631 shares but still holding 273,388 shares valued at approximately $65.9 million. Other institutional investors like Vanguard, Swedbank, and Nordea increased their positions, with institutional investors collectively owning 54.98% of ResMed. The company reported strong quarterly earnings, beating analyst estimates, and maintains a "Moderate Buy" consensus rating with an average target price of $286.18.
Inogen stock (US45780L1044): respiratory player in focus after Q1 2026 update and restructuring plan
Inogen has reported its Q1 2026 financial results, revealing shrinking revenues but also progress in cost-cutting and cash preservation. The company, which specializes in portable oxygen concentrators, is undergoing restructuring efforts to align its cost base with current revenue levels in a competitive US respiratory care market. Investors are now evaluating the impact of these changes on the company's future profitability and ability to innovate.
S&P Global Stock Testing Price Floor – Buy Now?
S&P Global (SPGI) stock is currently trading in a support zone where it has historically bounced, generating an average 18% peak return. The company's Q1 2026 results exceeded estimates, and analysts rate it a "Strong Buy" due to robust fundamentals, active share repurchases, and tailwinds from the expanding financial analytics market. Despite past drops during market crises, its current valuation appears undervalued compared to historical P/E ratios, suggesting a potential rebound.
With Strong Cash Flow, ResMed Stock Poised to Rise?
ResMed (RMD) stock appears to be an attractive investment due to its strong free cash flow yield of 5.9%, robust operating margin of 34.6%, and discounted valuation, trading 31% below its 2-year high. While individual stock trades carry risks, the company's fundamentals compare favorably to S&P medians. Trefis suggests considering a diversified portfolio strategy for better risk management.
Coeur Mining Stock To $23?
Coeur Mining (CDE) stock has dropped 13.6% in less than a month. Despite historical dips having a median 12-month return of -9.3%, Trefis maintains an "Attractive" opinion, suggesting a good chance of a rebound given the stock's quality checks. The article advises that while dip buying can be profitable, managing volatility requires a disciplined strategy like the Trefis High Quality Portfolio.
ResMed Inc stock (US75102W1036): Noctrix deal, dividend and shifting sentiment put sleep-therapy specialist back in focus
ResMed Inc. has agreed to acquire Noctrix Health for approximately $340 million, expanding its therapy portfolio. Simultaneously, the company declared a quarterly dividend of $0.60 per share, indicating confidence in its financial health. Despite a recent share price pullback in 2026, analysts maintain a "Moderate Buy" consensus, reflecting ongoing growth expectations and the strategic value of the acquisition alongside shareholder returns.
Wolverine World Wide, Inc. (NYSE:WWW) Given Consensus Recommendation of "Hold" by Brokerages
Wolverine World Wide, Inc. (NYSE:WWW) has received a consensus "Hold" rating from eleven brokerages, with an average 1-year price target of $21.75. The company recently surpassed first-quarter earnings and revenue expectations and raised its FY2026 EPS guidance, while also announcing a quarterly dividend. Major institutional investors have adjusted their holdings in the company.
ResMed Inc stock (AU000000RMD6): Noctrix deal and market cap slide in focus
ResMed Inc. is acquiring Noctrix Health for approximately $340 million, adding restless legs syndrome therapy to its portfolio, with the deal expected to close on June 1, 2026. This acquisition comes as ResMed's market capitalization has decreased by about 15% over the past year. The company, known for its sleep and respiratory care devices and software, continues to focus on integrating digital health solutions while navigating competitive and regulatory landscapes.
Needham reiterates Hold on ResMed stock on Noctrix acquisition By Investing.com
Needham maintained its "Hold" rating on ResMed (NYSE:RMD) following the announcement of its acquisition of Noctrix Health for $340 million, expected to close on June 1, 2026. While the acquisition is seen as beneficial for ResMed's revenue and EPS growth due to Noctrix's restless legs syndrome device, Nidra, Needham cited ongoing concerns about competitive threats from other treatments and Philips' potential re-entry into the market as reasons for the reiterated rating. Despite this, InvestingPro analysis suggests ResMed's stock might be undervalued, with several analysts revising earnings estimates upwards.
Needham reiterates Hold on ResMed stock on Noctrix acquisition
Needham reiterated a Hold rating on ResMed (NYSE:RMD) following its acquisition of Noctrix Health for $340 million, which is expected to close on June 1, 2026. While the acquisition of Noctrix, a company marketing a device for restless legs syndrome, could add to ResMed's revenue and EPS, Needham maintains its Hold rating due to competitive threats from drugs and Philips' potential re-entry into the market. This comes as ResMed recently reported mixed Q3 FY26 earnings, with an EPS beat but a revenue miss, and analysts holding differing views on its future performance.
ResMed Inc. stock (US7611521078): earnings beat, dividend and softer 2026 share price
ResMed Inc. reported stronger-than-expected quarterly earnings of $2.86 per share and revenue of $1.43 billion, marking a 10.8% increase year over year, along with a quarterly dividend of $0.60 per share. Despite these positive financial results and a "Moderate Buy" consensus from analysts, the stock's share price has declined by about 16% in 2026, trading significantly below its early 2026 highs and analysts' average price target. The company continues to focus on sleep and respiratory care devices, digital health platforms, and aims for ongoing growth driven by an aging population and increasing awareness of sleep apnea, while navigating competitive and regulatory risks.
ResMed Inc stock (US75102W1036): Strong earnings offset by market underperformance
ResMed Inc. reported strong Q1 2026 results with revenue up 10.8% year-over-year to $1.43 billion and EPS of $2.86, exceeding analyst estimates. Despite these operational gains, the stock has underperformed broader market indices, trading down 0.70% on the New York Stock Exchange. The company, a global leader in digital health and cloud-connected medical devices, continues to show strong fundamentals driven by recurring software revenue and exposure to healthcare trends, though near-term market sentiment remains cautious.
Jim Cramer Discusses the Performance of Danaher and Its Peers
Jim Cramer commented on Danaher Corporation (NYSE:DHR), calling it a "one-time excellent company" whose stock has been "pulverized" following multiple disappointing quarters. Despite its recent struggles, Cramer noted that Danaher is starting to see significant orders from biotechs, which could lead to a strong quarter. He also mentioned that several other medical and diagnostic companies are hitting new lows, indicating a broader struggle in the sector.
VIRGINIA RETIREMENT SYSTEMS ET Al Has $23.83 Million Position in ResMed Inc. $RMD
VIRGINIA RETIREMENT SYSTEMS ET Al reduced its stake in ResMed Inc. (NYSE:RMD) by 27.6% in the fourth quarter, holding 98,940 shares valued at approximately $23.83 million. ResMed reported strong quarterly results with EPS of $2.86 and revenue of $1.43 billion, and declared a quarterly dividend of $0.60 per share. Analysts currently rate the stock as a "Moderate Buy" with an average target price of $286.18, despite recent insider stock sales.
ResMed stock (US7611521078): Ex-dividend date arrives May 14 amid CEO option exercise
ResMed Inc. (US7611521078) is heading into its ex-dividend date on May 14, 2026, with a quarterly payout of $0.60 per share, amidst CEO Mick Farrell's exercise of stock options following a recent NYSE price drop. The company, a leader in respiratory and sleep care devices, reported strong revenue growth, with sales up 11% year-over-year to $1.29 billion in early 2026. This performance, coupled with a dominant position in the US sleep apnea market, positions ResMed favorably for investors, especially given competitor Philips' recall issues.
Swiss Life Asset Management Ltd Cuts Stake in ResMed Inc. $RMD
Swiss Life Asset Management Ltd significantly reduced its stake in ResMed Inc. by 34.3% in the fourth quarter, selling 14,421 shares, though its remaining holding is still valued at $6.65 million. ResMed reported strong quarterly earnings, beating estimates with EPS of $2.86 and revenue increasing by 10.8% to $1.43 billion, and also announced a dividend of $0.60 per share. Despite some insider selling and the stock trading near its 52-week low, analysts maintain a "Moderate Buy" consensus with an average price target of $286.18.
ResMed stock (US7611521078): ex-dividend date approaches on May 14
ResMed Inc. announces its ex-dividend date for May 14, 2026, with a quarterly payout of $0.60 per share to be distributed on June 18, 2026. The medical device manufacturer, listed on the NYSE, specializes in sleep apnea and respiratory care products and cloud-based software, maintaining a strong market position and appealing to US investors with its consistent dividends and exposure to digital health trends. The stock recently traded at $203.79, and the company's core business model focuses on recurring revenue from consumables and innovative connected devices.
ResMed stock (US7611521078): CEO exercises options amid NYSE price drop
ResMed's CEO, Mick Farrell, exercised stock options during a recent share price decline on the NYSE. The company, a leader in respiratory care, is also nearing its ex-dividend date of May 14, 2026, with a $0.60 per share payout. Despite the recent price weakness, ResMed remains a key player in the sleep health market, benefiting from strong US market demand.
Is ResMed a Better Buy Than Stryker?
This article compares ResMed (RMD) and Stryker (SYK) stocks, suggesting that ResMed is a better investment due to superior revenue growth, higher profitability, and a relatively lower valuation. It presents detailed financial metrics and historical market performance for both companies, highlighting RMD's lead in key areas. The analysis also briefly touches on the inherent risks in stock investment and suggests a portfolio approach for smart investing.
ResMed Inc. stock rises Tuesday, outperforms market
Shares of ResMed Inc. (RMD) advanced 2.53% to $203.79 on Tuesday, outperforming the broader market. This rise broke a three-day losing streak for the stock, despite a mixed trading session where the Dow Jones Industrial Average rose and the S&P 500 Index fell.
ResMed stock (US7611521078): CEO exercises options amid NYSE price drop
ResMed CEO Mick Farrell exercised stock options and sold shares under a 10b5-1 plan as the NYSE-listed stock dropped 3.7% to $199.12. The company, a leader in sleep apnea and respiratory care devices, maintains a Buy rating from analysts with an A$48.00 target. ResMed continues to lead in the market with robust product lines and digital innovation, offering stability for investors.
Could Cash Machine Abbott Laboratories Stock Be Your Next Buy?
Abbott Laboratories (ABT) is presented as a potentially attractive investment due to its high free cash flow yield of 5.1%, strong operating margin of 17.1%, and a discounted valuation. The article highlights that ABT stock is trading significantly below its 2-year and 1-month highs, offering a good entry point. It also compares ABT's fundamentals to S&P medians and suggests alternatives like Booking, Marsh & McLennan, and PayPal for investors seeking similar characteristics.
A Look at ResMed Inc (RMD) After 3.9% Decline -- GF Value $270.0
ResMed Inc (RMD) shares recently dropped 3.9%, trading at $198.76, which is significantly below its GF Value™ of $270.01, indicating it is 26.4% undervalued. Despite a strong GF Score™ of 97/100, highlighting excellent profitability and growth, recent insider selling of $4.9 million without any buying activity suggests potential caution among company insiders. Investors should weigh the undervaluation opportunity against these insider actions and market conditions.
ResMed CEO Farrell Exercises Options and Trims Stake Under 10b5-1 Plan
ResMed Inc. Chairman and CEO Michael J. Farrell exercised stock options for 4,991 shares and subsequently sold them under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, Farrell maintains a significant direct and indirect stake in the company. This activity reflects ongoing insider transactions but does not indicate any shift in leadership or company strategy.
